About Kabra Drugs Limited
Data last updated: 10 March 2026
Kabra Drugs Limited is a public limited company based in Indore, Madhya Pradesh, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 22 August 1989, the company has been in operation for over 37 years.
Registered with ROC Gwalior under CIN L02423MP1989PLC005438. Listed on BSE: 524322.
Capital: an authorised share capital of ₹40 Cr and a paid-up capital of ₹23.71 Cr. It is led by directors including Kuniamuthur Nanjappan Anand and Anand Anitha.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Indore, Madhya Pradesh.
As per the financials filed for FY 2025, the company reported a revenue of ₹64.02 Lakh, a growth of 0% compared to the previous year.
The company has a workforce of approximately 37 employees as per the latest available data.
As per MCA filings, the company has satisfied charges of ₹1.99 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website kabradrugs.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered Address208 Swadesh Bhavan, 2 Press Complex Ab Road, Indore, Madhya Pradesh, India – 452011
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Kabra Drugs Limited
Kabra Drugs Limited has one previous CIN (Corporate Identification Number): U02423MP1989PLC005438. The current CIN is L02423MP1989PLC005438, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L02423MP1989PLC005438 | Current |
| U02423MP1989PLC005438 | Previous |
Auditor Details of Kabra Drugs Limited
Kabra Drugs Limited is audited by P P N And Company (ICAI peer reviewed, certificate valid till 2028-09-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| P P N And Company (ICAI peer reviewed, certificate valid till 2028-09-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Kabra Drugs Limited
Kabra Drugs Limited is currently managed by 7 directors, with 24 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Kuniamuthur Nanjappan Anand
Also directs:
Drushya Entertainment Broadcast Streams Limited
|
Director | 09 Jun 2022 | 4 Years 1 Months | Current |
| Anand Anitha | Director | 14 Jul 2022 | 3 Years 11 Months | Current |
| Nanjappan Aravind | Additional Director | 14 Aug 2024 | 1 Years 10 Months | Current |
| Nikita Sinha | Director | 08 Oct 2025 | 0 Years 9 Months | Current |
|
Ritu Tiwari
Also directs:
Blue Pearl Agriventures Limited, Kcd Industries India Limited
|
Director | 08 Oct 2025 | 0 Years 9 Months | Current |
Financials of Kabra Drugs Limited FY 2026 filings available
Kabra Drugs Limited reported revenue of ₹92.74 Cr (up ) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹92.74 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Income | ₹49.27 Lakh | ₹64.02 Lakh | ₹0 | ₹64,000 | ₹0 | ₹0 | ₹0 |
| Total Income | ₹93.23 Cr | ₹64.02 Lakh | ₹0 | ₹64,000 | ₹0 | ₹0 | ₹0 |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹83.66 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹1.47 Cr | ₹69.23 Lakh | ₹40.04 Lakh | ₹23.16 Lakh | ₹8.93 Lakh | ₹4.8 Lakh | ₹0 |
| Finance Costs | ₹3 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Depreciation & Amortisation | ₹7.11 Lakh | ₹73,000 | ₹0 | ₹0 | ₹1 Lakh | ₹3.12 Lakh | ₹0 |
| Other Expenses | ₹2.28 Cr | ₹1.03 Cr | ₹33.57 Lakh | ₹11.27 Lakh | ₹8.61 Lakh | ₹10.08 Lakh | ₹85,000 |
| Total Expenses | ₹87.51 Cr | ₹1.73 Cr | ₹73.61 Lakh | ₹34.43 Lakh | ₹18.54 Lakh | ₹18 Lakh | ₹85,000 |
| Profit Before Exceptional Items & Tax | ₹5.72 Cr | -₹1.09 Cr | -₹73.61 Lakh | -₹33.79 Lakh | -₹18.54 Lakh | -₹18 Lakh | -₹85,000 |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹5.72 Cr | -₹1.09 Cr | -₹73.61 Lakh | -₹33.79 Lakh | -₹18.54 Lakh | -₹18 Lakh | -₹85,000 |
| Total Tax Expense | ₹76.09 Lakh | ₹5,000 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | ₹4.96 Cr | -₹1.09 Cr | -₹73.61 Lakh | -₹33.79 Lakh | -₹18.54 Lakh | -₹18 Lakh | -₹85,000 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹4.96 Cr | -₹1.09 Cr | -₹73.61 Lakh | -₹33.79 Lakh | -₹18.54 Lakh | -₹18 Lakh | -₹85,000 |
| EBITDA (computed) | ₹5.82 Cr | -₹1.08 Cr | -₹73.61 Lakh | -₹33.79 Lakh | -₹17.54 Lakh | -₹14.88 Lakh | -₹85,000 |
| Basic EPS | ₹2.09 | ₹-0.99 | ₹-1.68 | ₹-0.77 | ₹-0.42 | ₹-0.41 | ₹-0.02 |
| Diluted EPS | ₹2.09 | ₹-0.99 | ₹-1.68 | ₹-0.77 | ₹-0.42 | ₹-0.41 | ₹-0.02 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹86.27 Cr | ₹25.23 Cr | ₹4.57 Cr | ₹70.36 Lakh | ₹72.97 Lakh | ₹1.4 Cr | ₹1.69 Cr |
| Non-current Assets | ₹2.21 Cr | ₹6.71 Lakh | ₹2.32 Lakh | ₹2.32 Lakh | ₹2.32 Lakh | ₹3.32 Lakh | ₹21.97 Lakh |
| Current Assets | ₹84.06 Cr | ₹25.16 Cr | ₹4.55 Cr | ₹68.04 Lakh | ₹70.65 Lakh | ₹1.37 Cr | ₹1.47 Cr |
| Property, Plant & Equipment | ₹70.22 Lakh | ₹4.39 Lakh | ₹0 | ₹0 | ₹0 | ₹1 Lakh | ₹11.17 Lakh |
| Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Trade Receivables | ₹70.78 Cr | ₹60.05 Lakh | ₹60.05 Lakh | ₹60.05 Lakh | ₹60.05 Lakh | ₹1.25 Cr | ₹1.26 Cr |
| Cash & Equivalents | ₹10.58 Cr | ₹21.3 Cr | ₹11.65 Lakh | ₹15,000 | ₹4,000 | ₹90,000 | ₹10.68 Lakh |
| Equity (Net Worth) | ₹29.61 Cr | ₹24.65 Cr | ₹1.08 Cr | -₹73.1 Lakh | -₹39.31 Lakh | -₹20.77 Lakh | ₹18.81 Lakh |
| Equity Share Capital | ₹23.71 Cr | ₹23.71 Cr | ₹4.39 Cr | ₹4.39 Cr | ₹4.39 Cr | ₹4.39 Cr | ₹4.39 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹1.38 Cr | ₹0 | ₹0 | ₹1.08 Lakh |
| Borrowings (Current) | ₹42.91 Lakh | ₹43.74 Lakh | ₹1.71 Cr | ₹0 | ₹1.03 Cr | ₹90.05 Lakh | ₹65.25 Lakh |
| Total Debt (computed) | ₹42.91 Lakh | ₹43.74 Lakh | ₹1.71 Cr | ₹1.38 Cr | ₹1.03 Cr | ₹90.05 Lakh | ₹66.33 Lakh |
| Current Liabilities | ₹56.54 Cr | ₹57.39 Lakh | ₹3.49 Cr | ₹5.27 Lakh | ₹1.12 Cr | ₹1.61 Cr | ₹1.49 Cr |
| Total Liabilities | ₹56.66 Cr | ₹57.44 Lakh | ₹3.49 Cr | ₹1.43 Cr | ₹1.12 Cr | ₹1.61 Cr | ₹1.5 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹9.47 Cr | -₹4.71 Cr | -₹20.85 Lakh | -₹35.44 Lakh | -₹13.38 Lakh |
| Investing Cash Flow | -₹1.36 Cr | -₹5.13 Lakh | ₹0 | ₹0 | ₹0 |
| Financing Cash Flow | ₹11.5 Lakh | ₹23.39 Cr | ₹2.88 Cr | ₹35.61 Lakh | ₹12.53 Lakh |
| Capital Expenditure | ₹70.17 Lakh | ₹5.13 Lakh | ₹0 | ₹0 | ₹0 |
| Free Cash Flow (computed) | -₹10.18 Cr | -₹4.76 Cr | -₹20.85 Lakh | -₹35.44 Lakh | -₹13.38 Lakh |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹10.72 Cr | ₹18.63 Cr | ₹2.67 Cr | ₹17,000 | -₹85,000 |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹35.41 Cr | ₹30.42 Cr | ₹19.76 Cr | ₹7.15 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Income | ₹11.31 Lakh | ₹18.43 Lakh | ₹17.87 Lakh | ₹1.62 Lakh | ₹64.02 Lakh | ₹0 | ₹0 | ₹0 |
| Total Income | ₹35.52 Cr | ₹30.6 Cr | ₹19.94 Cr | ₹7.17 Cr | ₹64.02 Lakh | ₹0 | ₹0 | ₹0 |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹2.09 Cr | ₹41.78 Cr | ₹33.05 Cr | ₹6.75 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹30.98 Cr | -₹14.45 Cr | -₹16.52 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹34.56 Lakh | ₹38.53 Lakh | ₹35.7 Lakh | ₹37.81 Lakh | ₹25.13 Lakh | ₹19.21 Lakh | ₹14.3 Lakh | ₹10.59 Lakh |
| Finance Costs | ₹1.47 Lakh | ₹25,000 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Depreciation & Amortisation | ₹1.75 Lakh | ₹1.27 Lakh | ₹1.2 Lakh | ₹34,000 | ₹55,000 | ₹13,200 | ₹5,000 | ₹0 |
| Other Expenses | ₹65.5 Lakh | ₹27.93 Lakh | ₹84.46 Lakh | ₹53.46 Lakh | -₹93,000 | ₹34.27 Lakh | ₹25.25 Lakh | ₹43.98 Lakh |
| Total Expenses | ₹34.1 Cr | ₹28 Cr | ₹17.74 Cr | ₹7.67 Cr | ₹24.75 Lakh | ₹53.61 Lakh | ₹39.6 Lakh | ₹54.57 Lakh |
| Profit Before Exceptional Items & Tax | ₹1.42 Cr | ₹2.6 Cr | ₹2.21 Cr | -₹49.99 Lakh | ₹39.27 Lakh | -₹53.61 Lakh | -₹39.6 Lakh | -₹54.57 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1.42 Cr | ₹2.6 Cr | ₹2.21 Cr | -₹49.99 Lakh | ₹39.27 Lakh | -₹53.61 Lakh | -₹39.6 Lakh | -₹54.57 Lakh |
| Total Tax Expense | ₹35.68 Lakh | ₹40.22 Lakh | ₹36.83 Lakh | ₹0 | -₹10,000 | ₹7,400 | ₹7,000 | ₹0 |
| Net Profit | ₹1.06 Cr | ₹2.57 Cr | ₹1.84 Cr | -₹49.99 Lakh | ₹39.37 Lakh | -₹53.69 Lakh | -₹39.67 Lakh | -₹54.57 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹1.06 Cr | ₹2.57 Cr | ₹1.84 Cr | -₹49.99 Lakh | ₹39.37 Lakh | -₹53.69 Lakh | -₹39.67 Lakh | -₹54.57 Lakh |
| EBITDA (computed) | ₹1.45 Cr | ₹2.62 Cr | ₹2.22 Cr | -₹49.65 Lakh | ₹39.82 Lakh | -₹53.48 Lakh | -₹39.55 Lakh | -₹54.57 Lakh |
| Basic EPS | ₹0.45 | ₹1.08 | ₹0.77 | ₹-0.21 | ₹0.21 | ₹-0.53 | ₹-3.94 | ₹-1.24 |
| Diluted EPS | ₹0.45 | ₹1.08 | ₹0.77 | ₹-0.21 | ₹0.21 | ₹-0.53 | ₹-3.94 | ₹-1.24 |
Shareholding Pattern of Kabra Drugs Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, retail and other public shareholders hold 100.00% of Kabra Drugs Limited. The company had 9,185 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | - | - | - | - | - | - |
| Public | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | - | - | - |
| Public | 100.00% | 100.00% | 100.00% |
| Promoter change (YoY, %pts) | - | - | - |
Charges & Borrowings of Kabra Drugs Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Dec 2014 | Religare Finvest Limited | ₹1.51 Cr | Satisfied |
| 13 Nov 2010 | Bank of India | ₹48 Lakh | Satisfied |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Kabra Drugs Limited
View historical data on people associated with Kabra Drugs Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Kabra Drugs Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Kabra Drugs Limited
GSTIN & GST Filing Data of Kabra Drugs Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Kabra Drugs Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Kabra Drugs Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Kabra Drugs Limited
MSME Payment Delays by Kabra Drugs Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Kabra Drugs Limited
Subsidiaries & Group Companies of Kabra Drugs Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Kabra Drugs Limited with ownership details.
MCA Filings & Documents of Kabra Drugs Limited
MCA Filings & Documents of Kabra Drugs Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Kabra Drugs Limited
Frequently Asked Questions about Kabra Drugs Limited
Kabra Drugs Limited is an active public limited company in the pharma sector based in Indore, Madhya Pradesh, India. It was incorporated on 22 August 1989 (37+ years old) and is registered under CIN L02423MP1989PLC005438. Listed on BSE: 524322. The company has 37 employees.
Kabra Drugs Limited reported revenue of ₹64.02 Lakh for FY 2025 (up 0.00% YoY).
The current directors of Kabra Drugs Limited are:
- Kuniamuthur Nanjappan Anand
- Anand Anitha
- Monika Nishant Gattani
- Nanjappan Aravind
- Nikita Sinha
- Ritu Tiwari
- Pavanasam
The primary industry of Kabra Drugs Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Kabra Drugs Limited is listed on BSE with code 524322.
Kabra Drugs Limited can be reached at the registered office: 208 Swadesh Bhavan, 2 Press Complex Ab Road, Indore, Madhya Pradesh, India – 452011, or through the website kabradrugs.com.